Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

52.54USD
11:47am EST
Change (% chg)

$0.29 (+0.56%)
Prev Close
$52.25
Open
$51.83
Day's High
$52.67
Day's Low
$51.13
Volume
185,904
Avg. Vol
438,958
52-wk High
$53.89
52-wk Low
$20.29

ABMD.O

Chart for ABMD.O

About

ABIOMED, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $2,136.75
Shares Outstanding(Mil.): 40.89
Dividend: --
Yield (%): --

Financials

  ABMD.O Industry Sector
P/E (TTM): 121.72 31.52 40.64
EPS (TTM): 0.43 -- --
ROI: 9.80 8.13 18.12
ROE: 10.35 13.16 18.97
Search Stocks

Abiomed raises revenue outlook, wins US approval for heart pump

- Medical device maker Abiomed Inc raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump, sending its stock up about 30 percent in extended trading.

27 Jan 2015

UPDATE 2-Abiomed raises revenue outlook, wins US approval for heart pump

Jan 27 - Medical device maker Abiomed Inc raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump, sending its stock up about 30 percent in extended trading.

27 Jan 2015

CORRECTED-UPDATE 1-Abiomed raises revenue outlook, wins US approval for heart pump

Jan 27 - Medical device maker Abiomed Inc raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump, sending its stock nearly 32 percent in extended trading.

27 Jan 2015

Abiomed raises revenue outlook, wins U.S. approval for heart pump

- Medical device maker Abiomed Inc raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump, sending its stock nearly 32 percent in extended trading.

27 Jan 2015

UPDATE 1-Abiomed raises revenue outlook, wins US approval for heart pump

Jan 27 - Medical device maker Abiomed Inc raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump, sending its stock nearly 32 percent in extended trading.

27 Jan 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks